SIC
KYMR icon

SJS Investment Consulting’s Kymera Therapeutics KYMR Stock Holding History

SJS Investment Consulting’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459 Hold
4
– – ﹤0.01% 2297
2026
Q1 		$334 Sell
4
-30
-88% -$2.38K ﹤0.01% 1864
2025
Q4 		$2.65K Buy
34
+33
+3,300% +$2.23K ﹤0.01% 1080
2025
Q3 		$57 Hold
1
– – ﹤0.01% 1600
2025
Q2 		$44 Buy
+1
New +$34 ﹤0.01% 1523

Other funds holding KYMR

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return

SJS Investment Consulting's KYMR Position: Q2 2026 in Review

SJS Investment Consulting held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 4 shares worth $459. The position accounts for ﹤0.01% of the portfolio, ranked #2297.

SJS Investment Consulting first reported a position in KYMR in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.65K in Q4 2025. 49 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • SJS Investment Consulting held 4 shares of Kymera Therapeutics worth $459 as of Q2 2026.
  • SJS Investment Consulting left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2297 holding.
  • SJS Investment Consulting first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • SJS Investment Consulting's Kymera Therapeutics position peaked at $2.65K in Q4 2025.
  • 49 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.